Analysis of the env V3 sequences obtained from patients with HIV type 1 infection treated with the immune modulant agent tucaresol.
Tucaresol, a Schiff base-forming compound that is shown to enhance cytotoxic T cell responses and the production of type 1 cytokines, represents a potentially useful adjuvant factor for treating HIV-1 infection. We studied the effect of tucaresol on V3 sequences within the HIV-1 env region derived from patients with different virologic and immunologic features who were enrolled in a phase I/II randomized clinical trial. The sequence analysis of the env V3 region of the viruses at baseline has confirmed a genotypic pattern similar to a macrophagotropic virus model; we analyzed the follow-up sequences at week 16 of the protocol and did not observe any difference in the tropism determinants within the third variable fragment of the env region. The administration of tucaresol did not accelerate env V3 evolution thus preventing modifications of HIV-1 tropism over time.
Bulgheroni
Elisabetta
E
Institute of Infectious and Tropical Diseases, University of Milan, Ospedale Luigi Sacco, 20157 Milan, Italy.
Bandera
Alessandra
A
Galli
Massimo
M
Gori
Andrea
A
Rusconi
Stefano
S
D000595:Amino Acid Sequence; D001547:Benzaldehydes / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D015699:HIV Envelope Protein gp120 / Q000235:genetics*; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000235:genetics*; D016415:Sequence Alignment; D013997:Time Factors; D016896:Treatment Outcome
D001547:Benzaldehydes; D001565:Benzoates; D015699:HIV Envelope Protein gp120; C059762:HIV envelope protein gp120 (305-321); D007155:Immunologic Factors; D010446:Peptide Fragments; C059629:tucaresol